SCHEMBL740054

SCHEMBL740054

CCON1CCN(c2ccccc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 3/20 0.58
▸ DRD2 P14416 2/20 0.55
▸ SIGMAR1 Q99720 2/20 0.55
▸ DRD4 P21917 2/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ CYP3A4 P08684 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ CHRNB2 P17787 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ CHRNA3 P32297 1/20 0.46
▸ CHRNA4 P43681 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ GFER P55789 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8550989 0.85 DRD2 (0.56) CHRNA7DRD2SIGMAR1DRD4KCNH2
SCHEMBL14896053 0.80 CHRNA7 (0.49) CHRNA7DRD2SIGMAR1DRD4KCNH2
SCHEMBL8780413 0.80 DRD2 (0.50) CHRNA7DRD2SIGMAR1DRD4KCNH2
SCHEMBL17149208 0.79 HSD11B1 (0.45) DRD4MAPK1HSD17B10ALDH1A1MAPT
SCHEMBL2115191 0.78 CHRNA7 (0.53) CHRNA7DRD2SIGMAR1DRD4KCNH2
SCHEMBL28124792 0.78 ALDH1A1 (0.60) DRD2MAPK1ALDH1A1MAPTKDM4E
SCHEMBL15361051 0.77 CHRNA7 (0.58) CHRNA7DRD2SIGMAR1DRD4KCNH2
Hydrochloric Acid SCHEMBL27845680 0.76 CHRNA7 (0.52) CHRNA7DRD2SIGMAR1DRD4KCNH2
Hydrochloric Acid SCHEMBL11552188 0.76 CHRNA7 (0.52) CHRNA7DRD2SIGMAR1DRD4KCNH2
SCHEMBL576454 0.76 LMNA (0.67) CHRNA7DRD2SIGMAR1DRD4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286418-B2 Compounds and methods for treating or preventing bacterial infections BAYLOR COLLEGE OF MEDICINE (US) 2025-04-29 — — US disclosed
US-20220267303-A1 Compounds and Methods for Treating or Preventing Bacterial Infections BAYLOR COLLEGE OF MEDICINE 2022-08-25 — — US disclosed
WO-2020257734-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, OR PREVENTING BACTERIAL INFECTIONS BAYLOR COLLEGE OF MEDICINE (US) 2020-12-24 — — WO disclosed
US-8901116-B2 Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-12-02 — — US disclosed
US-20140088095-A1 METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-03-27 — — US disclosed
US-8541409-B2 Carbamoyloxy arylalkanoyl arylpiperazine analgesics SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-09-24 — — US disclosed
US-8138342-B2 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds High Point Pharmacueticals, LLC (US) 2012-03-20 — — US disclosed
EP-2155736-B1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO LTD (KR) 2011-12-21 — — EP disclosed
US-20110195963-A1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-08-11 — — US disclosed
US-20100160331-A1 NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO. LTD. (KR) 2010-06-24 — — US disclosed
EP-2155736-A1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK Holdings Co., Ltd. (KR) 2010-02-24 — — EP disclosed
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds NOVO NORDISK A/S (DK) 2009-04-23 — — US disclosed
WO-2008140198-A1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO., LTD. (KR) 2008-11-20 — — WO disclosed
EP-1802623-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS Novo Nordisk A/S (DK) 2007-07-04 — — EP disclosed
WO-2006040329-A1 1 IBETA- HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE SPIRO COMPOUNDS NOVO NORDISK A/S (DK) 2006-04-20 — — WO disclosed
EP-0836599-A1 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES PHARMACIA & UPJOHN COMPANY (US) 1998-04-22 — — EP disclosed
US-4147869-A ADRENERGIC BLOCKING AGENTS FOR TREATMENT OF ANGINA PECTORIS, ARRHYTHMIA AND HYPERTENSION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1979-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160331-A1 NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND HTR5A, OPRD1, OPRL1 CHRNA7 71/4885DRD2 381/4885SIGMAR1 315/4885
US-20220267303-A1 Compounds and Methods for Treating or Preventing Bacterial Infections OXA1L, MMP8, OGG1 CHRNA7 4760/4885DRD2 3147/4885SIGMAR1 2731/4885
US-20110195963-A1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND HTR5A, CNR2, CNR1 CHRNA7 67/4885DRD2 543/4885SIGMAR1 407/4885
US-12286418-B2 Compounds and methods for treating or preventing bacterial infections OXA1L, MMP8, OGG1 CHRNA7 4760/4885DRD2 3147/4885SIGMAR1 2731/4885
US-20090105289-A1 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds HSD11B1, HSD3B1, HSD17B1 CHRNA7 2864/4885DRD2 2168/4885SIGMAR1 1813/4885
US-20140088095-A1 METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND HTR5A, OPRL1, HDAC3 CHRNA7 119/4885DRD2 702/4885SIGMAR1 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback